No abstract

prostatectomy (change: 1.389 QALY), proportions of distant metastasis (change: -0.930 QALY) and high-risk patients (change: 0.641 QALY), and treatment effect of radical prostatectomy (change: -0.593 QALY). The lifetime direct medical costs associated with PC patients was highly sensitive to mortality (change: U-67,231) and treatment effects of surgical castration therapy (change: U-50,422), brachytherapy combined with external beam radiation therapy (change: U47,440), and androgen deprivation therapy (change: U-41,375). The probabilistic sensitivity analysis with 5,000 Monte Carlo simulations estimated the median and 95% credible interval of reduced QALY (-1.813 QALY, -2.382 to -1.154 QALY) and increased lifetime direct medical costs (U283,506, U210,436 to U405,878). Conclusions: The disease burden of PC in Chinese patients was mainly characterized with increased medical costs that were highly sensitive to treatments during the disease course.